Skip to content
RushPR News – Lifestyle
Author:
Matisse Pharmaceuticals
Matisse Pharmaceuticals closed Series A financing round to advance isupartob sodium through phase 2 clinical development
September 17, 2026
Matisse Pharmaceuticals receives FDA Fast Track Designation for isupartob sodium in sepsis
June 9, 2026
Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium
May 19, 2026